

# MindMed

09:27 16 Nov 2020

## MindMed reports a current cash position of C\$50.1M

MindMed (NEO:MMED) (OTCQB:MMEDF) late Friday announced that it has a current cash reserve of US\$37.8 million, or C\$50.1 million, after closing a C\$28.8 million financing on October 30, 2020.

The company said its current cash position will enable it to continue to advance its clinical trial pipeline of psychedelic-inspired medicines and experiential therapies.

The October bought-deal equity financing saw the company issue 23,810,000 shares at a price C\$1.05 per share. MindMed said part of the proceeds will help fund ongoing research and development work on psilocybin in collaboration with the University Hospital Basel's Liechti Lab in Switzerland to better understand and compare the altered states of consciousness induced by psilocybin and LSD. It added that the funds will also go towards the development of 18-MC, a non-hallucinogenic molecule derivative of ibogaine from the African plant iboga, as a way to treat opioid use disorder.

### READ: MindMed wraps up Phase 1 LSD study in partnership with Swiss lab; prepares for Phase 2 of 'Project Lucy'

The company also recorded a 3Q net and comprehensive loss of US\$8.6 million.

MindMed announced recently that it has completed a Phase 1 study on the acute dose-dependent effects of LSD in partnership with University Hospital Basel's Liechti Lab in Switzerland, to help treat patients with anxiety disorders and other medical conditions.

The company also said its team is actively preparing what it is calling Project Lucy, to evaluate the efficacy of LSD-assisted therapy for anxiety disorders in a Phase 2b clinical trial.

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness, with a drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC.

Contact Sean at [sean@proactiveinvestors.com](mailto:sean@proactiveinvestors.com)

**Price:** 3.32

**Market Cap:** \$1.08 billion

### 1 Year Share Price Graph



March 2020 August 2020 February 2021

### Share Information

**Code:** MMEDF

**Listing:** OTCQB

52 week	High	Low
	5.07	0.0833

**Sector:** Pharma & Biotech

**Website:** [www.mindmed.co](http://www.mindmed.co)

### Company Synopsis:

*MindMed is a neuropharmaceutical drug development platform advancing medicines based on psychedelic substances through rigorous science and clinical trials. MindMed's mission is to discover, develop and deploy psychedelic inspired medicines that alleviate suffering and improve health.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MindMed named herein, including the promotion by the Company of MindMed in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).